Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

GEIGER COUNTER LIMITED Share Issue/Capital Change 2020

Jan 6, 2020

7665_rns_2020-01-06_f4ae32c8-f657-41c9-88f5-46100ede85b3.html

Share Issue/Capital Change

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8882Y

Geiger Counter Ltd

06 January 2020

6 January 2020

GEIGER COUNTER LIMITED

(THE "COMPANY")

Issue of Ordinary Shares

The Company announces that, conditional only on Admission becoming effective, it has allotted, by way of a new issue in response to market demand, 625,000 new ordinary shares of no par value (the "New Shares") for cash, at a price of 15.50p per share, a premium to the Company's net asset value. The New Shares will rank pari passu with the existing ordinary shares.

Applications have been made for the New Shares to be admitted to The International Stock Exchange's Listing and to trading on the London Stock Exchange's SETSqx platform ("Admission"). Admission is expected to become effective, and dealings in the New Shares are expected to commence, at 8.00 a.m. on 9 January 2020.

Following the issue of the New Shares, the Company's issued share capital will consist of 84,266,611 ordinary shares and 37,420,104 subscription shares, none of which are held in treasury.

Enquiries

CQS (UK) LLP Craig Cleland T: +44 (0) 20 7201 5368
finnCap Limited William Marle/Giles Rolls T: +44 (0) 20 7220 0500
R&H Fund Services (Jersey) Limited Jane De Barros-Sousa T :+44 (0) 1534 825 259

Important Information

The information contained in this announcement does not constitute an offer of securities for sale in any jurisdiction.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

IOEKKABBQBKDPDK